Ultima Genomics Powers Singapore's Precision Medicine Leap

Ultima Genomics' UG200 Sequencing Platform has been chosen to support Singapore's National Precision Medicine (NPM) program, Phase III. This major initiative, branded as the SG-INSIGHT cohort, will involve nearly 450,000 individuals, nearly 10% of Singapore's population, with a focus on participants receiving medical treatment.

The NPM Phase III program represents a significant expansion, shifting towards integrating genomics into clinical care and healthcare delivery. Ultima's selection follows extensive evaluation, highlighting the quality, clinical readiness, and cost-effectiveness of its latest technology, including the UG200 system and Solaris 2.0 chemistry. The company is collaborating with Lucence, a Singapore-based clinical lab, and QIAGEN, a global leader in sequencing technologies.

This collaboration aims to generate evidence supporting the integration of genetic screening into public healthcare. Ultima will provide sequencing and genomic analysis capabilities, while Lucence handles clinical program management and QIAGEN supports sample preparation. The initiative is expected to advance precision medicine at a population scale and strengthen Ultima's presence in the Asia-Pacific region.